DDInter927 DDInter1863
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452]
Triclabendazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Triclabendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Triclabendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Triclabendazole {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Triclabendazole {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Triclabendazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Triclabendazole may lead to a major life threatening interaction when taken with Vemurafenib
Triclabendazole may lead to a major life threatening interaction when taken with Ivosidenib